Company / Return on Equity (ROE)
Acadia Pharmaceuticals Return on Equity (ROE) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
31.9%
FY2025
5-year range
-53.9% / 31.9%
FY2021-FY2025
Trend
+3.1%
vs FY2024
Sector context
#15 of 190
Health Care
What the data says
Among 190 Health Care companies, Acadia Pharmaceuticals is in the top 8% for return on equity (roe). Return on Equity (ROE) has increased for 3 consecutive years, from -53.9% in FY2022 to 31.9% in FY2025.
Based on SEC 10-K filings.
31.9% in FY2025 with a 5-year CAGR of +76.8%. Top quartile in the Health Care sector.
Improved from -14.2% to 31.9% over the past 2 years.
Health Care sector context is included.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- +85.8pp
- 5-Year Change
- +76.8pp
- 10-Year Change
- -
Sector benchmark
+163.2% above sector average
Key checks
Key Insights
- Acadia Pharmaceuticals's return on equity (roe) has grown for 3 consecutive years.
- In FY2025, return on equity (roe) increased 3.1% year-over-year.
- Currently 82.3pp above the Health Care sector average.
- Lowest return on equity (roe) in the period was in FY2017.
Company context
Key Data Points
- Strong profit margin: 24.9%
- Low earnings quality (accrual-heavy earnings)
- Strong return on equity: 28.5%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | 31.9% | +3.1% |
| FY2024 | 30.9% | +317.8% |
| FY2023 | -14.2% | +73.7% |
| FY2022 | -53.9% | -73.8% |
| FY2021 | -31.0% | +30.9% |
| FY2020 | -44.9% | -33.5% |
| FY2019 | -33.7% | +34.3% |
| FY2018 | -51.2% | +40.7% |
| FY2017 | -86.3% | -64.9% |
| FY2016 | -52.3% | +36.4% |
As of FY2025 · SEC 10-K · Updated Jul 1, 2026